Comparative effectiveness of GLP-1 receptor agonists versus mineralocorticoid receptor antagonists as fourth-line pharmacological therapy in patients with resistant hypertension and overweight or obesity: a retrospective multicenter cohort study in the USA.
BACKGROUND: Mineralocorticoid receptor antagonists (MRAs) are the guideline-recommended therapy for resistant hypertension. Prospective studies are needed to determine whether GLP-1RAs should be incorporated into treatment strategies for resistant hypertension in patients with overweight or obesity.
BACKGROUND: Mineralocorticoid receptor antagonists (MRAs) are the guideline-recommended therapy for resistant hypertension. Prospective studies are needed to determine whether GLP-1RAs should be incorporated into treatment strategies for resistant hypertension in patients with overweight or obesity.
What the study was
- Study design
- Prospective Cohort Study
- Category
- Prevention
- Maturity
- Validated
- Journal
- EClinicalMedicine
Why it surfaced
Matched watchlist topic(s): Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk. Study design: Prospective Cohort Study. Score 8/10. 🟢 Near-term implementable finding.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.